Oyanagui Y
2nd Pharmacology, Drug Develop. Lab. of Fujisawa Pharmaceut. Co., Osaka, Japan.
Life Sci. 1996;58(17):PL287-94. doi: 10.1016/0024-3205(96)00119-1.
Dexamethasone (Dex, 0.3 mg/kg, s.c.) did not suppress histamine and ischemic paw edema of mice up to 1 hr. However, given TGF-beta 1 (0.3 microgram/kg, i.p.), Dex suppression appeared early as 30 min (36% and 42%). When Dex (0.1 mg/kg, s.c.) was injected 6 hr before the assay, Dex alone, TGF-beta 1 +/- Dex, FK506 (10 mg/kg, oral) +/- Dex, cyclosporin (CsA, 30 mg/kg, oral) +/- Dex, rapamycin (Rapa, 10 mg/kg, i.p.) +/- Dex, deoxyspergualin (DSP, 10 mg/kg, i.p.) +/- Dex, did not suppress the edemata (less than 11%). Nevertheless, if Dex and TGF-beta 1 were dosed together with one of these immunosuppressants, suppressions of histamine and ischemic edema were 53%, 45% (FK506), 45%, 49% (CsA), 44%, 48% (Rapa) and 39%, 51% (DSP), respectively. Glucocorticoid (GC) receptor (GR) complex contains heat shock proteins such as hsp56 (or CsA-binding protein: CyP-40), hsp70 and hsp90. FK506, Rapa and TGF-beta 1 receptor I (TR-I) bind FK-binding protein-12 (FKBP-12). FK506 and Rapa bind also hsp56. CsA binds CyP-40. DSP binds hsp70 and/or hsp90. These bindings might change or stabilize the conformation of GR complex resulting in edema suppressions. Nitric oxide synthase (NOS) inhibitors, superoxide dismutase (SOD), catalase, mannitol and cycloheximide, reversed the edema suppressions by TGF-beta1 +/- immunosuppressant at 30 min and 6 hr after Dex. Endogenous NO, O2- and/or .OH seemed to be essential for edema suppressions. Our demonstration in vivo may offer a theoretical support for clinicians to adopt combination therapy of immunosuppressant(s) and GC.
地塞米松(Dex,0.3毫克/千克,皮下注射)在长达1小时内未抑制小鼠的组胺和缺血性爪水肿。然而,给予转化生长因子-β1(TGF-β1,0.3微克/千克,腹腔注射)后,地塞米松的抑制作用早在30分钟时就出现了(分别为36%和42%)。当在检测前6小时皮下注射地塞米松(0.1毫克/千克)时,单独使用地塞米松、TGF-β1±地塞米松、他克莫司(FK506,10毫克/千克,口服)±地塞米松、环孢素(CsA,30毫克/千克,口服)±地塞米松、雷帕霉素(Rapa,10毫克/千克,腹腔注射)±地塞米松、去氧精胍菌素(DSP,10毫克/千克,腹腔注射)±地塞米松,均未抑制水肿(抑制率低于11%)。然而,如果地塞米松和TGF-β1与这些免疫抑制剂之一同时给药,则组胺和缺血性水肿的抑制率分别为53%、45%(FK506)、45%、49%(CsA)、44%、48%(Rapa)和39%、51%(DSP)。糖皮质激素(GC)受体(GR)复合物包含热休克蛋白,如hsp56(或CsA结合蛋白:CyP - 40)、hsp70和hsp90。FK506、Rapa和TGF - β1受体I(TR - I)与FK结合蛋白 - 12(FKBP - 12)结合。FK506和Rapa也与hsp56结合。CsA与CyP - 40结合。DSP与hsp70和/或hsp90结合。这些结合可能会改变或稳定GR复合物的构象,从而导致水肿抑制。一氧化氮合酶(NOS)抑制剂、超氧化物歧化酶(SOD)、过氧化氢酶、甘露醇和环己酰亚胺在给予地塞米松后30分钟和6小时时,逆转了TGF - β1±免疫抑制剂对水肿的抑制作用。内源性一氧化氮、超氧阴离子和/或羟自由基似乎对水肿抑制至关重要。我们的体内研究结果可能为临床医生采用免疫抑制剂和糖皮质激素联合治疗提供理论支持。